Form D · Biotechnology
Mimerigen, Inc.
Guilford, CT · CIK 0002029689
Offering snapshot reported Jul 31, 2024 · SEC filing
- Reported sold
- $105K Offering amount: $700K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 17, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 31, 2024 | Initial | $105,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-520263
SAFE's
Source: Form D, filed Jul 31, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William Hansen | Director, Executive |
| Per Langoe | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
351 Tanner Marsh Road
Guilford, CT, 06437
Guilford, CT, 06437